PharmaShots’ Key Highlights of Second Quarter 2021

The US FDA has approved 6 NDAs and 2 BLAs in 2021, leading to treatments for patients and advances in the health care industry The Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have approved 37 novel products in 2021 Additionally, last year in 2020, the US FDA…

BySenior EditorJuly 7, 2021

TOP 20

Top 20 Prescription Drugs Based on 2019 Revenue

The average life expectancy span of Human Beings are increased due to better medical facilities and drugs developed by Biopharma companies. Pharmaceutical products or drugs or medicines are being produced for a wide range of medical sectors. It includes the lifesaving drugs or the major therapy area including immunology- cardiology- and neurology but are they…

ByPrince GiriJuly 17, 2020

TOP 20

Top 20 BioPharma Companies based on 2019 Total Revenue

The global biopharma companies are developing novel therapies & devices which is- in turn- enhancing their portfolio and encouraging them in this undergoing competition to stay in the topmost position The top 20 companies chartbusters changed their 2019 ranking- but the history of Johnson and Johnson did not change and it continued being at the…

ByPrince GiriApril 24, 2020

INSIGHTS+

Insights+: Key Deals of J.P. Morgan Healthcare Conference 2020

The 2020 JP Morgan Healthcare Conference was loaded with insights from key pharma companies. An analysis of events and catalysts that were announced or updated at the conference these days are included. Our PharmaShots team summarized the key deals which were presented during the updates from companies from Jan 13 to Jan 16, 2020. Date…

BySenior EditorFebruary 7, 2020

INSIGHTS+

PharmaShots’ Most Read News of 2019

The year 2019 has been a busy year for global pharma and biotech companies involved in M&A, option & licensing agreements and gaining approvals. Our team has compiled a list of 20 most read life sciences news on PharmaShots in 2019. 1. Celltrion Signed an Exclusive Co-Marketing Agreement with Juno in Australia Juno provided sales promotion…

BySenior EditorJanuary 10, 2020

INSIGHTS+

Insights+: The US FDA New Drug Approvals in September and October 2019

The US FDA's Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have approved 35 new products so far in 2019. In 2018 FDA approved 59 novel products including 42 New Chemical Entities and 17 Biologics while breaking its last year's record of approvals. However, there is a significant…

BySenior EditorNovember 15, 2019

INSIGHTS+

PharmaShots’ Key Highlights of First Quarter 2019

The first quarter of 2019 has marked with major events in the pharma & biotech industries. We have gathered the key highlights of the quarter, which was starting with the blockbuster news, where Celgene had acquired BMS for $74B. Moving to the next news, acquisition of Loxo Oncology for $8B, in addition to Spark Therapeutics…

BySenior EditorAugust 4, 2019

TOP 20

Top 20 BioPharma Companies based on 2018 Total Revenue

The global pharma companies have been advancing their pipelines with emerging needs of patients. Pharma companies are also focusing on diagnostics & devices- which were emerged as one of major revenue generator in 2018- with the development of new products and devices. The year 2018 also proved to be a record with approval of 55…

ByPrince GiriMay 1, 2019

PharmaShots’ Key Highlights of Second Quarter 2021

Top 20 Prescription Drugs Based on 2019 Revenue

Top 20 BioPharma Companies based on 2019 Total Revenue

Insights+: Key Deals of J.P. Morgan Healthcare Conference 2020

PharmaShots’ Most Read News of 2019

Insights+: The US FDA New Drug Approvals in September and October 2019

PharmaShots’ Key Highlights of First Quarter 2019

Top 20 BioPharma Companies based on 2018 Total Revenue

Contact US

FOLLOW US